FindTrial
Sign In

Efficacy and safety of high versus standard radiation dose of definitive chemoradiotherapy combined with immunotherapy for unresectable esophageal squamous cell carcinoma: a multicenter propensity score matching analysis

Efficacy and safety of 60Gy versus 50.4 Gy radiation dose of definitive chemoradiotherapy combined with immunotherapy for unresectable esophageal squamous cell carcinoma: a retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094445
Enrollment
Unknown
Registered
2024-12-23
Start date
2023-10-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

high-dose group:NA
standard dose group:NA

Sponsors

Department of Radiation Oncology, Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Inoperable locally advanced (TanyNanyM0) or advanced (TanyNanyM1) esophageal squamous cell carcinoma with supraclavicular lymph node metastasis only according to the 8th edition of the American Joint Committee on Cancer (AJCC 8th) cancer staging system; (2) Definitive chemoradiotherapy combined with anti-PD-1 antibody therapy as the first-line treatment, in which chemotherapy needs to be administrated in induction or concurrent period, and anti-PD-1 antibody can be used in any phase; (3) cycles of chemotherapy and anti-PD-1 antibodies >= 2; (4) The interval between anti-PD-1 antibody and radiotherapy <= 6 months; (5) The radiation dose to the primary lesion is 50-50.4Gy or =60Gy.

Exclusion criteria

Exclusion criteria: (1) Pathology includes other types except squamous cell carcinoma; (2) Chemotherapy is only administrated in adjuvant period; (3) The cycle of chemotherapy and anti-PD-1 antibody is only one; (4) Incomplete medical information; (5) The radiation dose of the primary lesion was between 50.4 Gy and 60 Gy.

Design outcomes

Primary

MeasureTime frame
overall survival;progression-free survival;Locoregional failure rate;—

Countries

China

Contacts

Public ContactQiaoqiao Li

Department of Radiation Oncology, Sun Yat-sen University Cancer Center

liqq@sysucc.org.cn+86 137 1052 8306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026